BioNTech
WEBWe believe in scientific rigor, innovation and passion as driving force. BioNTech was founded by scientists and physicians to translate science into survival by combining fundamental research and operational excellence.
Scientific Publications - BioNTech
WEBPublications. We maintain a culture of scientific excellence and will continue to drive future innovation through sharing our key findings in a peer reviewed format. Discoveries and developments making mRNA powerful enough to serve as medicine. The picture above is showing the cover of the peer-reviewed journal Blood in which the BioNTech co ...
BNT162b2 mRNA COVID-19 Vaccine: First Approval - PMC
WEBMar 8, 2021 · BNT162b2 (Comirnaty ®; BioNTech and Pfizer) is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine for the prevention of the novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
WEBDec 10, 2020 · BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were...
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 …
WEBOct 4, 2021 · We aimed to evaluate overall and variant-specific effectiveness of BNT162b2 (tozinameran, Pfizer–BioNTech) against SARS-CoV-2 infections and COVID-19-related hospital admissions by time since vaccination among members of a …
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine …
WEBSep 15, 2021 · BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...
How the Pfizer-BioNTech Vaccine Works - The New York Times
WEBThe Pfizer-BioNTech vaccine requires two injections, given 21 days apart, to prime the immune system well enough to fight off the coronavirus. But because the vaccine is so new, researchers...
BNT162b2 vaccine induces neutralizing antibodies and poly ... - Nature
WEBMay 27, 2021 · BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that encodes the SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has demonstrated 95% efficacy in...
Impact and effectiveness of mRNA BNT162b2 vaccine against ... - The Lancet
WEBMay 15, 2021 · Following the emergency use authorisation of the Pfizer–BioNTech mRNA COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel, the Ministry of Health (MoH) launched a campaign to immunise the 6·5 million residents of Israel aged 16 years and older.
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 …
WEBNov 18, 2020 · Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group.